Self-poisoning among adults using multiple transdermal nicotine patches

Journal of Toxicology - Clinical Toxicology

Volumn 34, Issue 6, 1996, Pages 691-698

  Woolf, Alan ^a,e   Burkhart, Keith ^b   Caraccio, Thomas ^c   Litovitz, Toby ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c WINTHROP UNIVERSITY HOSPITAL   (United States)

^d National Capital Poison Center   (United States)

^e Massachusetts Poison Control Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOYLECGONINE; COCAINE; DRUG METABOLITE; HOMOCOCAINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG ABUSE; GAS CHROMATOGRAPHY; HAIR ANALYSIS; HUMAN; MALE; MASS SPECTROMETRY;

EID: 0030472812     PISSN: 07313810     EISSN: None     Source Type: Journal    
DOI: 10.3109/15563659609013830     Document Type: Article

References (23)

1. Henningfield JE. Nicotine medications for smoking cessation. N Engl J Med 1995;333:1196-1203.
2. Gorsline J, Gupta SK, Dye D, Rolf CN. Nicotine dose relationships for Nicoderm (nicotine transdermal system) at steady state. Pharm Res 1991;10:S299.
3. Abelin T, Buehler A, Muller P, Vesanen K, Imhof PR. Controlled trial of transdermal nicotine patch in tobacco withdrawal. Lancet 1989;1:7-10.
4. Transdermal Nicotine Study Group. Transdermal nicotine for smoking cessation. Six-month results from two multicenter controlled clinical trials. JAMA 1991;266:3133-3138.
5. Fiore MC, Jorenhy DE, Baker TB, Kenford SL. Tobacco dependence and the nicotine patch. Clinical guidelines for effective use. JAMA 1992;268:2687-2694.
6. Fiore MC, Smith SS, Jorenby DE, Baker TB. The effectiveness of the nicotine patch for smoking cessation. A meta-analysis. JAMA 1994;271:1940-1947.
7. Orleans CT, Resch N, Noll E, Keintz MK, Rimer BK, Brown TV, Snedden TM. Use of transdermal nicotine in a state-level prescription plan for the elderly. JAMA 1994;271:601-607.
8. Kenford SL, Fiore MC, Jorenby DE, Smith SS, Wetter D, Baker TB. Predicting smoking cessation. Who will quit with and without the nicotine patch. JAMA 1994;271:589-594.
9. Gourlay S. The pros and cons of transdermal nicotine therapy. Med J Aust 1994;160:152-159.
10. Hughes JR. Risk-benefit assessment of nicotine preparations in smoking cessation. Drug Saf 1993;8: 49-56.
11. Anonymous. Nicotine patches. Med Lett Drug Ther 1992;34:37-38.
12. Fazier CA. Side effects of nicotine patches. JAMA 1993;270:2735.
13. Fiore M, Hartman MJ. Side effects of nicotine patches. JAMA 1993;270:2735.
14. Dwyer CM, Forsyth A. Allergic contact dermatitis from methacrylates in a nicotine transdermal patch. Contact Dermatitis 1994;30:309-310.
15. Vincenzi C, Tosti A, Cirone M, Guarrera M, Cusano F. Allergic contact dermatitis from transdermal nicotine systems. Contact Dermatitis 1993;29:104-105.
16. Farm G. Contact allergy to nicotine from a nicotine patch. Contact Dermatitis 1993;29:214-215.
17. Warner JG Jr, Little WC. Myocardial infarction in a patient who smoked while wearing a nicotine patch. Ann Intern Med 1994;120:695.
18. Dacosta A, Guy JM, Tardy B, et al. Myocardial infarction and nicotine patch: a contributing or causative factor? Eur Heart J 1993;14:1709-1711.
19. Engel CJ, Parmentier AH. Suicide attempts and the nicotine patch. JAMA 1993;270:323-324.
20. SmithKline Beecham Clinical Laboratories: Reference range for blood nicotine/cotinine concentrations for smokers (8-70 cigarettes/day), Van Nuys, California.
21. Saxena K, Scheman A. Suicide plan by nicotine poisoning: a review of nicotine toxicity. Vet Hum Toxicol 1985;27:495-497.
22. Lavoie FW, Harris TM. Fatal nicotine ingestion. J Emerg Med 1991;9:133-136.
23. Benowitz NL, Jacob P III; Olsson P, Johansson CJ. Intravenous nicotine retards transdermal absorption of nicotine: evidence of blood flow-limited percutaneous absorption, Clin Pharmacol Ther 1992;52:223-230.